February 14, 2022
Fresenius again has Germany’s best online offering for job seekers, Potentialpark study for 2022 finds
The market research institute Potentialpark has honored the global healthcare group Fresenius for the 11th consecutive year as the German company with the best overall Internet offering for job applicants.
In Potentialpark’s 2022 study, Fresenius not only took first place in the overall category for all career-relevant online activities, but also won in the individual categories of mobile offering and online application management. Fresenius finished second in the career presence in social media category, and seventh for career website.
Potentialpark has carried out an annual study of German companies’ online offerings for job seekers since 2002. For this year’s study, Potentialpark evaluated the online activities of 140 companies in Germany according to more than 350 criteria. More than 43,000 students and graduates around the world were surveyed about their preferences.
“Digital channels have played a big part in our communications with potential applicants for years, and during the pandemic these digital contact points have become even more important,” said Jennifer Weihs, Head of Corporate Human Resources at Fresenius. “That makes us especially happy about our latest success in the Potentialpark ranking. And in future we aim to continue offering all job seekers the best possible information, as well as a simple online application process.”
The quality of Fresenius’ internet offering has been confirmed in an additional study, by the RheinMain University of Applied Sciences. It analyzed and evaluated the career websites of 138 major German employers, and ranked Fresenius third overall.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.